Cong Yan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Interests
Cong Yan has a total of 22 co-authors. Here are the top co-authors by number of shared publications:
Songmei Geng
The Second Affiliated Hospital of Xi’an JiaoTong University
4 shared publicationsKun Guo
The Second Affiliated Hospital of Xi’an JiaoTong University
2 shared publicationsTong Zhou
Department of Dermatology the Second Affiliated Hospital of Xi'an Jiaotong University Xi'an Shaanxi China
2 shared publicationsZhaowei Chu
The Second Affiliated Hospital of Xi’an JiaoTong University
2 shared publications- Bingjie Li
Department of Dermatology, Northwest Hospital, The Second Hospital Affiliated to Xi'an Jiaotong University, Xi'an, China
1 shared publication Delu Che
The Second Affiliated Hospital of Xi’an JiaoTong University
1 shared publication
Latest Publications
- 1 November 2026
- Published by Institute of Electrical and Electronics Engineers (IEEE) in IEEE Transactions on Radiation and Plasma Medical Sciences
- Vol. 10 (8) , 1361-1371
Plasma-Activated Liquid Modulated the Efficacy and Resistance of Targeted Therapy Agents in Melanoma Cells With BRAFV600E Mutation
Targeted therapy is the first-line treatment for melanoma patients harboring the BRAFV600E mutation. However, the development of drug resistance significantly limits its clinical efficacy and long-term patient survival benefits. Cold atmospheric plasma (CAP) has emerged as a promising adjunctive oncotherapy. Plasma-activated liquid (PAL), the indirect application of CAP, exhibits superior tissue penetration capabilities and has been extensively investigated in animal models. Previous study from our group indicated that PAL can sensitize melanoma cells to targeted therapeutic agents in vitro. However, therapeutic efficacy has not yet been evaluated in animal models. This study aimed to evaluate the combined effect of PAL and targeted therapy in BRAFV600-mutant melanoma both in vitro and in vivo. Results demonstrated that PAL enhanced the efficacy of targeted therapy and sensitized A2058 cells to the BRAF inhibitor GSK2118436. Furthermore, the combination of intratumoral PAL injection with targeted therapy significantly inhibited the growth of subcutaneous melanoma tumors in vivo. In conclusion, our findings suggest that PAL represents a novel and promising combined strategy for melanoma treatment.
- 1 November 2026
- Published by Institute of Electrical and Electronics Engineers (IEEE) in IEEE Transactions on Radiation and Plasma Medical Sciences
- Vol. 10 (8) , 1361-1371
Plasma-Activated Liquid Modulated the Efficacy and Resistance of Targeted Therapy Agents in Melanoma Cells With BRAFV600E Mutation
Targeted therapy is the first-line treatment for melanoma patients harboring the BRAFV600E mutation. However, the development of drug resistance significantly limits its clinical efficacy and long-term patient survival benefits. Cold atmospheric plasma (CAP) has emerged as a promising adjunctive oncotherapy. Plasma-activated liquid (PAL), the indirect application of CAP, exhibits superior tissue penetration capabilities and has been extensively investigated in animal models. Previous study from our group indicated that PAL can sensitize melanoma cells to targeted therapeutic agents in vitro. However, therapeutic efficacy has not yet been evaluated in animal models. This study aimed to evaluate the combined effect of PAL and targeted therapy in BRAFV600-mutant melanoma both in vitro and in vivo. Results demonstrated that PAL enhanced the efficacy of targeted therapy and sensitized A2058 cells to the BRAF inhibitor GSK2118436. Furthermore, the combination of intratumoral PAL injection with targeted therapy significantly inhibited the growth of subcutaneous melanoma tumors in vivo. In conclusion, our findings suggest that PAL represents a novel and promising combined strategy for melanoma treatment.
- 5 November 2025
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 146 (6) , 1553-1570.e8
MRGPRX2-Mediated Mast Cell Activation Promotes Malignant Progression of Cutaneous Squamous Cell Carcinoma through IL-17A Release
- 5 November 2025
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 146 (6) , 1553-1570.e8
MRGPRX2-Mediated Mast Cell Activation Promotes Malignant Progression of Cutaneous Squamous Cell Carcinoma through IL-17A Release
- 19 December 2023
- Published by Wiley in Journal of Biophotonics
- Vol. 17 (3) , e202300356
Cold atmospheric plasma sensitizes melanoma cells to targeted therapy agents in vitro
Cold atmospheric plasma (CAP) has been reported to kill melanoma cells in vitro and in vivo. BRAF and MEK inhibitors are targeted therapy agents for advanced melanoma patients with BRAF mutations. However, low overall survival and relapse‐free survival are still tough challenges due to drug resistance. In this study, we confirmed that CAP alleviated innate drug resistance and promoted the anti‐tumor effect of targeted therapy in A875 and WM115 melanoma cells in vitro. Further, we revealed that CAP altered the expression of various molecules concerning MAPK and PI3K‐AKT pathways in A875 cells. This study demonstrates that CAP promises to work as adjuvant treatment with targeted therapy to overcome drug resistance for malignant tumors in future.
- 19 December 2023
- Published by Wiley in Journal of Biophotonics
- Vol. 17 (3) , e202300356
Cold atmospheric plasma sensitizes melanoma cells to targeted therapy agents in vitro
Cold atmospheric plasma (CAP) has been reported to kill melanoma cells in vitro and in vivo. BRAF and MEK inhibitors are targeted therapy agents for advanced melanoma patients with BRAF mutations. However, low overall survival and relapse‐free survival are still tough challenges due to drug resistance. In this study, we confirmed that CAP alleviated innate drug resistance and promoted the anti‐tumor effect of targeted therapy in A875 and WM115 melanoma cells in vitro. Further, we revealed that CAP altered the expression of various molecules concerning MAPK and PI3K‐AKT pathways in A875 cells. This study demonstrates that CAP promises to work as adjuvant treatment with targeted therapy to overcome drug resistance for malignant tumors in future.
- 20 March 2023
- Published by Wiley in The Journal of Dermatology
- Vol. 50 (9) , E278-E279
Chinese nontwin sisters suffer from poikiloderma with neutropenia harboring novel compound heterozygous USB1 gene mutations
- 20 March 2023
- Published by Wiley in The Journal of Dermatology
- Vol. 50 (9) , E278-E279
Chinese nontwin sisters suffer from poikiloderma with neutropenia harboring novel compound heterozygous USB1 gene mutations
- 31 May 2022
- Published by Wiley in Dermatologic Therapy
- Vol. 35 (8) , e15587
Hydroxychloroquine‐induced acute generalized exanthematous pustulosis in an orofacial granulomatosis patient with homozygous IL36RN mutation
- 31 May 2022
- Published by Wiley in Dermatologic Therapy
- Vol. 35 (8) , e15587
Hydroxychloroquine‐induced acute generalized exanthematous pustulosis in an orofacial granulomatosis patient with homozygous IL36RN mutation